Heidelberg University, officially the Ruprecht Karl University of Heidelberg, is a public research university in Heidelberg, Baden-Württemberg, Germany. Founded in 1386 on instruction of Pope Urban VI, Heidelberg is Germany's oldest university and one of the world's oldest surviving universities.

During the past decade, Ruprecht - Karls - Universitaet Heidelberg conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ruprecht - Karls - Universitaet Heidelberg" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 5 trials, followed by "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 2 trials sponsored, "H. Lundbeck A/S" with 1 trials sponsored, "Heidelberg University" with 1 trials sponsored and "Shire" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ruprecht - Karls - Universitaet Heidelberg" #1 collaborator was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Ruprecht - Karls - Universitaet Heidelberg" are "Leukemia" (5 trials), "Myelodysplastic Syndromes" (4 trials), "Lymphoma" (3 trials), "Myelodysplastic/Myeloproliferative Neoplasms" (2 trials) and "Acute Antibody-Mediated Rejection (AMR)" (1 trials). Many other conditions were trialed in "Ruprecht - Karls - Universitaet Heidelberg" in a lesser frequency.

Most popular intervention types in "Ruprecht - Karls - Universitaet Heidelberg" are "Drug" (9 trials), "Biological" (5 trials), "Procedure" (3 trials), "Radiation" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (3 trials), "cytarabine" (3 trials), "Placebo" (2 trials), "allogeneic bone marrow transplantation" (2 trials) and "doxorubicin hydrochloride" (2 trials). Other intervention names were less common.

The vast majority of trials in "Ruprecht - Karls - Universitaet Heidelberg" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Ruprecht - Karls - Universitaet Heidelberg". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Ruprecht - Karls - Universitaet Heidelberg, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ruprecht - Karls - Universitaet Heidelberg, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".